Therapeutic Phlebotomy in Polycythemia Vera
Phlebotomy is the cornerstone of treatment for all PV patients, regardless of risk category, and involves removing blood to maintain hematocrit below 45% to prevent thrombotic complications. 1, 2, 3
What Phlebotomy Does
Phlebotomy works by:
- Reducing red blood cell mass to lower blood viscosity
- Maintaining hematocrit <45%, which has been shown to reduce thrombosis risk
- Creating controlled iron deficiency that limits erythropoiesis (though this can cause symptoms)
The target hematocrit of <45% is universally recommended across all major guidelines 4, 5, 1, 2, 3. This specific threshold is critical—maintaining hematocrit below this level significantly reduces thrombotic events.
Phlebotomy Protocol
Initial Phase
- At diagnosis, patients typically present with hematocrit around 54% 6
- Perform phlebotomy every 2-3 days initially, removing 250-500 mL per session
- Continue until hematocrit reaches <45%
- Most patients achieve target hematocrit within 12 months 6
Maintenance Phase
- Monitor hematocrit regularly (every 1-3 months depending on stability)
- Perform phlebotomy as needed to maintain hematocrit <45%
- Approximately 19% of low-risk patients require >5 phlebotomies per year during maintenance 6
Clinical Reality: Suboptimal Control
Real-world data reveals concerning gaps in hematocrit control despite phlebotomy. Among patients treated with phlebotomy alone, only 36% at 6 months, 44% at 12 months, and 32% at 24 months maintained adequate hematocrit control 6. In another study, 54-64% of patients sometimes or always had hematocrit levels >50%, well above the target 7. This suggests phlebotomy alone may be insufficient for many patients.
Iron Deficiency: The Double-Edged Sword
Repeated phlebotomy inevitably causes iron deficiency, which can produce:
- Fatigue and lethargy
- Impaired concentration
- Pica (craving non-food items)
- Mouth paresthesia
- Restless legs syndrome 4, 8
Iron supplementation should only be given when severe tissue iron deficiency causes detrimental symptoms 4. If iron supplementation worsens hematocrit control, this indicates the need for cytoreductive therapy rather than continued iron replacement.
When Phlebotomy Alone Is Insufficient
Indications to add cytoreductive therapy include:
- High-risk disease (age >60 years or prior thrombosis) 4, 5, 3
- Requirement for frequent phlebotomies (>5 per year causing poor quality of life)
- Progressive thrombocytosis
- Symptomatic or progressive splenomegaly
- Severe disease-related symptoms
- Platelet count >1500 × 10⁹/L or leukocyte count >15 × 10⁹/L 4
Context for Hematospermia
In a patient presenting with hematospermia, phlebotomy serves to:
- Immediately reduce thrombotic risk by lowering hematocrit
- Address the underlying hyperviscosity that may contribute to microvascular complications
- Provide baseline treatment while assessing need for additional cytoreduction
The hematospermia itself represents a microvascular manifestation of PV. All patients should also receive aspirin 81 mg once or twice daily (unless contraindicated) to further reduce thrombotic risk 1, 2, 3. The combination of phlebotomy to maintain hematocrit <45% plus aspirin forms the foundation of treatment for all PV patients.
Outcomes with Phlebotomy
Among low-risk PV patients treated with phlebotomy alone, the thrombosis incidence rate is 0.8% per year, with 10-year thrombosis probability of 8.5% 6. Ten-year survival probability is 97% 6, demonstrating that phlebotomy-based management is effective for appropriately selected patients, though newer agents like hepcidin mimetics (rusfertide) are being developed to control hematocrit without requiring repeated phlebotomy 8.